India urology drugs market is
anticipated to grow with an estimated CAGR in the forecast years FY2023-FY2027,
on the grounds of increasing instances of urology diseases and urinary tract
disorders. Increasing advancement in the pharmaceutical industry regarding
urinary disease treatment is further driving the growth of the India urology
drugs market in the upcoming five years.
Urology drugs are the pharmaceuticals
that are used a treatment for urogenital conditions and diseases like urinary
inconsistences, prostatic hyperplasia, and erectile dysfunctions. Urology is a
part of healthcare sector that deals with the diseases of male and female
urinary tract including reproductive organs. Urinary tract includes organs like
kidney, ureters, bladder, and urethra.
Reproductive organs like penis, testes,
scrotum, prostate, etc. involved in the conditions is also treated with use of
urology drugs. Advancing pharmaceutical industry is consistently developing
various therapeutic drugs like Detrol (tolterodine), Enablex (darifenacin), Oxytrol
or Ditropan XL (oxybutynin), Regurin and Sanctura (trospium chloride), Toviaz
(fesoterodine), Vesicare (solifenacin), Sanctura (trospium).
Increasing Instances of Urinary Diseases
Drive Market Growth
Rapidly increasing instances of urinary
diseases and disorders in the country is anticipated to further drive the
growth of the India urology drugs market in the upcoming five years. Approximately,
800 per million population in India have risk of chronic kidney diseases as per
the report from 2020. The increasing risk of prostate cancer also supports the
growth of the India urology drugs market in the next five years. Prostate
cancer is the second leading site of cancer instances in the Indian males in
metro cities like Delhi, Kolkata, Pune and Thiruvananthapuram.
Advancing Pharma Industry Supports
Market Growth
Rapidly increasing advancement and
product development is driving the growth of the India urology drugs market in
the upcoming five years. Moreover, increasing investment in the research sector
of the drug development is further anticipated to support the growth of the
India urology drugs market in the next five years. Recent drug developments
like antimuscarinic and beta-3-agonist drugs advances the growth of the India
urology drugs market in the future five years.
Also, therapeutic drugs like Detrol
(tolterodine), Enablex (darifenacin), Oxytrol or Ditropan XL (oxybutynin),
among other urology drugs are some of the advanced pharmaceutical products that
are further substantiating the growth of the India urology drugs market in the
forecast years.
Click here to download the sample
Market Segmentation
The India
urology drugs market segmentation is based on drug class, type, application,
distribution channel, competitional landscape, and regional distribution. Based
on drug class, the market is further fragmented into anticholinergic/ antispasmodic agents,
skeletal muscle relaxants, alpha blockers, and others. Also based on
type, the market is further divided between original drugs and generic drugs.
Based
on application, the market is segmented into benign prostatic hyperplasia (BPH), prostate cancer, urinary
incontinence, kidney/bladder stone, erectile dysfunction, and others. The
market segmentation based on distribution channel is bifurcated into hospital pharmacies, retail pharmacies, and
online. The market analysis also studies the regional segmentation to devise
regional market segmentation, divided among North India region, South India
region, East India region, and West India region.
Company Profile
Astellas Pharma India Pvt Ltd, Endo
Pharmaceuticals, Sanofi India, Pfizer Ltd., Innovexia Lifesciences, Salvus
Pharma, Silhos Pharma Ltd., are some of the major market players in the country
that lead the market growth analysis. New market players are also actively
entering the market in the recent years and further strengthening the growth of
the future market growth.
|
Attribute
|
Details
|
|
Base Year
|
FY2021
|
|
Historic Data
|
FY2017
– FY2020
|
|
Estimated Year
|
FY2022
|
|
Forecast Period
|
FY2023
– FY2027
|
|
Quantitative Units
|
Revenue in USD Million, volume in Thousand units and CAGR for FY2017
– FY2020 and FY2023 – FY2027
|
|
Report coverage
|
Revenue
forecast, volume forecast, company share, competitive landscape, growth factors,
and trends
|
|
Segments covered
|
- Drug Class
- Type
- Application
- Distribution Channel
|
|
Regional scope
|
North;
South; East; West;
|
|
Key companies profiled
|
Astellas Pharma India Pvt Ltd, Endo Pharmaceuticals, Sanofi
India, Pfizer Ltd., Innovexia Lifesciences, Salvus Pharma, Silhos Pharma Ltd.
|
|
Customization scope
|
10%
free report customization with purchase. Addition or alteration to country,
regional & segment scope.
|
|
Pricing and purchase options
|
Avail customized purchase options to meet your exact research
needs. Explore purchase options
|
|
Delivery Format
|
PDF
and Excel through Email (We can also provide the editable version of the
report in PPT/Word format on special request)
|
Report Scope:
In this report, India Urology drugs market is segmented into following
categories, in addition to the industry trends which have also been detailed
below:
- India Urology Drugs
Market, By Drug Class:
- Anticholinergic/
Antispasmodic Agents
- Skeletal
Muscle Relaxants
- Alpha
Blockers
- Others
- India Urology Drugs Market, By Type:
- Original
Drugs
- Generic
Drugs
- India Urology Drugs Market, By Application:
o
Benign
Prostatic Hyperplasia (BPH)
o
Prostate
Cancer
o
Urinary
Incontinence
o
Kidney/Bladder
Stone
o
Erectile
Dysfunction
o
Others
- India Urology Drugs Market, By Distribution
Channel:
- Hospital
Pharmacies
- Retail
Pharmacies
- Online
- India Urology Drugs Market, By Region:
Competitive Landscape
Company
Profiles: Detailed
analysis of the major companies present in India urology drugs market.
Available Customizations:
With the given market data, TechSci Research offers
customizations according to a company’s specific needs. The following
customization options are available for the report:
Company
Information
- Detailed analysis and profiling of
additional market players (up to five).
India Urology Drugs Market
is an upcoming report to be released soon. If you wish an early delivery of
this report or want to confirm the date of release, please contact us at [email protected]
In case you don’t find what you are looking for, please get in touch with our custom research team at [email protected]